BioStock: Lipum advances to phase II with capital raise, moves production to Sweden
On leap day, Lipum published the year-end report for 2023, where CEO Ola Sandborgh describes the progress as a “flying start to an exciting journey.” On the same day, Lipum announced a rights issue of SEK 187 million to advance SOL-116 into phase II. In addition, the company has decided to relocate its contract manufacturing of SOL-116 back to Sweden through an agreement with NorthX Biologics. Ola Sandborgh elaborates on the latest news in an interview.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se